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Objectives: Buprenorphine/naloxone (BUP/NAL) combination is a well known 
treatment for opioid dependence. As a chronic relapsing disorder, some patients 
alternate between periods of on treatment and off treatment. The aim of this 
study was to compare health care resource utilization and costs between these 
patients and patients treated continuously. MethOds: Statistical analyses were 
conducted on a Medicaid insurance claims database (TruvenHealth MarketScan® 
Medicaid) from January 2007 to June 2012. Patients with at least two treatment 
episodes in the first year after the initial filled prescription were identified. The 
end of a treatment episode was defined as a period of 60 days with no filled BUP/
NAL prescriptions following the theoretical end of the last filled prescription. An 
ordered logistic regression model was used to analyze the impact of initial treat-
ment episode duration on the number of new episodes in the year following the 
end of the first episode. Health care resource utilization and related costs during 
the first year after initiation were compared between the two groups. Results: 
2,223 patients were included in the analysis. During the first year, 86% of patients 
had only one treatment episode, 13% had two and 1% had three. Compared to 
patients who remained in treatment continuously over 12 months, the multiple 
treatment episode group had lower medication costs (-$2,877) but higher psychi-
atric inpatient costs (+$720), non-psychiatric inpatient costs (+$2001) and emer-
gency room costs (+430) over 12 months. Total health care costs over 12 months 
were higher among multiple treatment episode patients ($16,583 vs. $15.123, 
p= 0.0004). cOnclusiOns: Despite lower medication costs, total health care costs 
over 12 months were higher among patients with multiple treatment episodes 
compared to patients treated continuously.
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Objectives: To compare the treatment cost of paliperidone palmitate (PP) versus 
risperidone long acting (R-LA), both indicated for the treatment of schizophrenia in 
Brazil. MethOds: In Brazil, both (PP and R-LA) long acting 2nd generation antipsy-
chotics are approved for the treatment of schizophrenia. Published literature shows 
no difference in safety and efficacy between them; therefore, a cost-minimization 
analysis was performed. Yearly treatment costs were calculated for an average dose 
of 37,5 mg per patient in the case of R-LA and 75 mg in the case of PP. The two initial 
treatment doses were considered: for PP, 150 mg on the 1st day and 100 mg on the 
8th day, and for R-LA 21 days oral supplementation with 3 mg of risperidone, accord-
ing to dosing intervals defined in the product label. Prices were gathered from the 
official price list (CMED – Apr’14). Results: PP has the lowest cost of treatment, 
at R$ 12,739 per patient in the 1st year – against R-LA R$ 18,165 – and R$ 11,359 in 
the 2nd year (R-LA has R$ 17,971). Treatment with PP compared to R-LA may bring 
important savings to the payers (HMOs or Government), with potential to reduce 
the cost of treatment by 30% in the 1st year, and 37% in the 2nd year - allowing a 
higher number of patients to be treated at the same budget level. cOnclusiOns: 
Although both molecules, PP and R-LA, have demonstrated similar efficacy, PP offers 
a cost reduction from the perspective of the Brazilian private health care system 
compared to R-LA. In addition, PP offers advantages that can have additional value 
for public and private payers alike such as a monthly injection and no need for 
cold chain. PP can therefore be considered a cost-saving therapeutic option for 
schizophrenia compared to R-LA.
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Approximately 10-20% of individuals with Major Depressive Disorder (MDD) fail to 
respond to antidepressant monotherapy. These individuals with treatment resist-
ant depression (TRD) have been found to be frequent users of health care services, 
thus incurring significantly greater costs than those without TRD. Objectives: 
To investigate the cost of Treatment-Resistant Depression from a private payer 
perspective in Canada. MethOds: An employer-sponsored benefits plan data-
base (2011/2012) was used to define a cohort of Non-TRD and TRD claimants. TRD 
claimants are defined as those on their third antidepressant monotherapy; or 
combination antidepressant therapy; or antidepressant augmented with lithium, 
thyroid hormone or an antipsychotic medication. The cost of prescription medica-
tion utilization, short-term disability (STD), and long-term disability (LTD) benefits 
for employees was calculated (2011 and 2012 $CAN) for both Non-TRD and TRD 
groups. Descriptive statistics were used to characterize the cohort of claimants 
and employees, as well as resources and costs for employees. Results: There 
were 55,324 and 61,028 employee claimants in 2011 and 2012, respectively. 717 
(1.3%) and 798 (1.3%) were TRD claimants; 4,744 (8.6%) and 5,137 (8.4%) were Non-
TRD claimants in 2011 and 2012, respectively. In 2011, the medication costs for 
treating depression was $774 per TRD employee claimant compared to $303 per 
Non-TRD claimant. STD costs were $6,263 for TRD (n= 79) and $5,855 for Non-TRD 
(n= 276). LTD costs were $13,598 for TRD (n= 80) and $12,272 for Non-TRD (n= 119). 
In 2012, the medication costs for treating depression per TRD employee claimant 
was $794 compared to $293 for Non-TRD claimants. STD costs were $7,832 for TRD 
(n= 86) and $4,001 for Non-TRD (n= 248). LTD costs were $13,927 for TRD (n= 89) 
and $12,901 for Non-TRD (n= 121). cOnclusiOns: Claimants identified with TRD 
had higher medication, STD and LTD costs than those with Non-TRD. Limitations 
include lack of diagnostic information for claimants and small sample sizes for 
STD and LTD subgroups.
Objectives: Major depressive disorder affects approximately 10-15% of the popu-
lation and is associated with significant morbidity and mortality. It is one of the 
leading causes of disability in young adults. A large proportion of the burden can be 
attributed to treatment-resistant depression (TRD). To understand the prevalence 
and disease burden of TRD in Western European countries, the US and Canada, a 
systematic literature search was performed. MethOds: OVID, the Cochrane Library 
and the CRD database were used to retrieve TRD publications in English language 
from January 2003-October 2013. In total, 6306 abstracts were identified. Predefined 
selection criteria regarding study design, patient population (age ≥ 12 years; US, 
Canada, Germany, Italy, France, Spain or UK; TRD defined as one treatment failure 
and high symptom severity e. g. MADRS ≥ 31, or an inadequate response to ≥ two 
antidepressants) and outcomes of interest were applied. Results: Only seven stud-
ies included prevalence and/or disease burden data. Five studies provided preva-
lence estimates which adhered to the strict TRD definition used for this review. 
Study design and definition of the patient population were critical in determining 
the prevalence rates, with the lowest rates found in US employer claims databases 
(11-15%), higher rates in commercial health insurance databases (29-31%) and the 
highest rates in a European multicenter study (51-56%). The database studies mainly 
included employed patients thereby likely underestimating the prevalence, whereas 
the European study likely overestimated the prevalence due to a less stringent TRD 
definition. Inconsistent data were reported regarding treatment outcomes, comor-
bidities, hospitalization and work productivity. There was no information on other 
outcomes such as health-related quality of life or functioning. cOnclusiOns: No 
consistent data were found in the literature from January 2003-October 2013 regard-
ing the epidemiology and disease burden of TRD. To determine the prevalence and 
disease burden for TRD, further studies are needed.
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Objectives: The aim of this study was to estimate the prevalence of metabolic syn-
drome (MS) in patients with schizophrenia according to the presence or absence of 
negative symptoms. MethOds: A retrospective, cohort study was conducted using 
electronic medical records from the health provider BSA (Badalona, Spain). All adult 
outpatients with a diagnosis of schizophrenia were followed for 12 months. Two study 
groups were defined by the presence or absence of negative symptoms based on the 
PANSS Marder Negative Symptoms Factor (N1-N4, N6, G7 and G16). MS prevalence was 
estimated using the NCEP ATP III criteria. Descriptive statistics and logistic regres-
sion models were applied. Results: We studied 1,120 patients (mean age: 46.8 ± 
13.8 years; male: 58.4%). One or more negative symptoms were present in 52.5% of 
patients (95%CI: 49.6-55.4%). Dyslipidemia (48.7%), hypertension (38.2%), and diabetes 
mellitus (19.3%) were the most frequent comorbid conditions. Quetiapine, risperidone 
and olanzapine were the most common antipsychotic drugs administered. Patients 
with negative symptoms showed a greater mean number of comorbid conditions than 
patients without this symptomatology (8.5 and 7.0, respectively; p< 0.001). Prevalence 
of MS was 38.6% (CI: 35.7-41.5%), higher among patients with one or more negative 
symptoms (43.9% vs. 34.9%, respectively; p= 0.002). MS was associated with the pres-
ence of negative symptoms, age, and comorbidity (OR= 1.6, 1.2, and 1.2, respectively; 
p< 0.05). cOnclusiOns: Further studies are necessary to elucidate the association 
between the presence of negative symptoms and MS among patients with schizo-
phrenia as well as the underlying mechanisms involved.
MenTal HealTH – Cost studies
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Objectives: To quantify the economic burden of schizophrenia relapse in 
Brazil, and to estimate the impact of atypical Long Acting Injectables (LAIs) on 
relapse. MethOds: Administrative health service data from a Brazilian public system 
database (DATASUS) were used to estimate the number of relapse patients and related 
resource utilisation. Corresponding data for private system patients were estimated 
based on published literature and by extrapolating DATASUS data. A prevalence-based 
costing with a mixed bottom-up and top-down approach was used to quantify direct 
and indirect costs, disability adjusted life years (DALYS) and their associated monetary 
value. A decision-analytic model was constructed to evaluate the cost effectiveness 
of potentially transferring non-compliant patients from oral antipsychotics to atypi-
cal LAIs. All costs are presented in 2013 Brazilian real. Results: In 2011-12, 88,721 
patients with schizophrenia in Brazil experienced 263,037 episodes of relapse that 
resulted in hospital or outpatient care. The potential avoidable health care cost of 
relapse was R$722.6 million. The estimated additional health care cost per DALY 
avoided was R$5,049 if non-compliant patients could be transferred to atypical LAIs 
to achieve 5% overall utilisation. Reducing relapses would give Brazil potential avoid-
ance of 1,335 DALYs, which corresponds to a saving of R$482.8 million in the stock 
of health capital. cOnclusiOns: The economic burden of schizophrenia relapse in 
Brazil is significant. Brazilian policymakers should provide greater access to LAIs.
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6.6), both p< 0.05. A greater proportion of schizophrenia caregivers reported at 
least one emergency room visit (26.1% vs. 20.2%) and hospitalization (20.4% vs. 
14.3%) than other caregivers, both p< 0.05. No significant difference was found 
on work-related impairment, probably due to the small sample of employed 
respondents. cOnclusiOns: Schizophrenia caregivers reported greater activity 
impairment and more resource use than non-caregivers and caregivers of adults 
with other conditions. Better family and social support systems may help reduce 
the burden for schizophrenia caregivers.
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Objectives: To investigate medication usage patterns, health care resource 
utilization and direct medical costs of patients with Major Depressive Disorder 
(MDD) in Beijing, China. MethOds: Data were randomly extracted from Beijing 
Urban Employee Basic Medical Insurance Database. Patients who were aged ≥ 18 
years, with at least 1 primary diagnosis of MDD and 12-month continuous enroll-
ment after their first observed MDD diagnosis between 2012 and 2013 were identi-
fied. Those with a diagnosis of schizophrenia, bipolar disorder or cancer within the 
study period were excluded. Descriptive statistics were used to describe patient 
profiles, medication usage, health care resource utilization and costs. Results: 
A total of 8484 patients were included with mean (±SD) age of 57.15 (±15.34) 
years, 63.02% female and 94.47% having co-morbidities. 71.35% of patients were 
treated with antidepressant medications, including 60.53% of patients with SSRIs, 
followed by NaSSA (8.96%) and SNRIs (8.26%). Concomitant medications were 
prescribed for 76.78% of patients. Only 0.42% of patients experienced ≥ 1 MDD-
related hospitalizations during the 1-year follow up and the average annual num-
ber of hospitalization was 1.22 (±0.64) for those hospitalized patients. The length 
of stay was 33.38 (±30.6) days per hospitalization and 36.61 (±40.04) days per 
patient-year. All patients had ≥ 1 MDD-related outpatient visits. The mean annual 
number of outpatient visits was 3.06 (±2.99). The mean annual direct medical 
cost for all MDD patients was 1694.05 (±2513.71) RMB with 48.54% for antidepres-
sant medications, and that for hospitalized patients was 21290.97 (±16121.61) 
RMB with 15.03% for antidepressant medications and 66.45% for non-drug 
medical costs. cOnclusiOns: In Beijing China, most MDD patients also had co-
morbid conditions and were mainly treated in the outpatient setting. SSRIs were 
the most commonly used antidepressants. The economic burden of MDD was 
considerable.
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Objectives: Atomoxetine is the first medication to receive marketing authoriza-
tion in Spain for the treatment of newly diagnosed adults with Attention-Deficit/
Hyperactivity Disorder (ADHD). The aim of this analysis was to assess if treat-
ment with atomoxetine in adults with ADHD was cost-effective vs. placebo from 
the Spanish Healthcare System perspective. MethOds: A Markov state tran-
sition model was developed for a theoretical cohort of newly diagnosed adult 
patients with moderate-severe ADHD. Key input data (response and discon-
tinuation) were derived from the atomoxetine trial program. Patients enter the 
model at the age of 18 and receive atomoxetine (initiated at 40mg for a week and 
then titrated to 80mg or 100mg) or placebo (in the absence of another authorized 
medication for the treatment of newly diagnosed adults with ADHD). Treatment 
success has been defined as response to treatment, showing improvements in 
both symptoms and functioning as measured by the CAARS and CGI-S scales, 
respectively. Treatment, non-specific health state utilities were populated with 
estimates from a vignette study in adults conducted in the UK. Drug and direct 
medical costs were obtained from local databases. In accordance with other 
published ADHD models, a 1-year time horizon was used. To check the model 
for robustness, probabilistic and deterministic sensitivity analyses were per-
formed. Results: Atomoxetine was found to be cost-effective with an ICER of 
€ 24,248/QALY despite patients in placebo arm only accumulating cost of physician 
visits. In addition, a QALY gain of 0.023 was projected, due to greater proportion 
of patients responding to treatment in the atomoxetine arm. Results from a 
probabilistic sensitivity analysis indicated that atomoxetine has a 57% probabil-
ity of being more cost-effective than placebo at a willingness to pay threshold 
of € 30,000/QALY in the Spanish setting. cOnclusiOns: Atomoxetine is a cost-
effective option versus no active medical treatment for newly diagnosed adults 
with ADHD in Spain.
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Objectives: Schizophrenia is a heterogeneous chronic disease with enormous 
economic consequences for the society. This study aimed at building a conceptual 
framework to evaluate the cost-effectiveness of Aripiprazole Once-Monthly (AOM) 
versus other atypical long-acting injectable (LAI) antipsychotics: Risperidone LAI 
(RLAI), Paliperidone Palmitate (PP) and Olanzapine Pamoate (OP) in the mainte-
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Objectives: The objectives of this study are to estimate the prevalence of schizo-
phrenia in Switzerland and to assess its burden on patients, caregivers and society 
as a whole. MethOds: A hospital registry was combined with a physician survey 
and health insurance claims data to capture all patients living in the northern part 
of the canton of Zurich. Total costs included direct medical and non-medical costs 
and lost production. All costs were calculated for the year 2012 from a societal 
perspective using a prevalence-based bottom-up approach. Intangible costs were 
expressed as quality adjusted life years (QALY) lost and were calculated from Swiss 
life tables, standardized mortality ratios and utility weights from the literature. 
Uncertainty and its sources were addressed in univariate and probabilistic sensi-
tivity analysis. Results: The point prevalence of schizophrenia in 2012 was esti-
mated at 0.39% of the Swiss population. The average annual costs of schizophrenia 
amounted to EUR 39,408 per patient and consisted of direct medical costs of EUR 
9,507 (24%), the costs of care by relatives and in residential homes of EUR 4,793 
(12%) and lost production of EUR 25,108 (64%). Inpatient hospital care accounted 
for EUR 6,242 per year or 66% of direct medical costs. The estimated reduction in 
life expectancy of 10.46 years and the utility decrement of 22.05 percentage points 
lead to intangible costs of 19.02 QALY per incident chronic case. cOnclusiOns: 
The results of this study show the high burden of schizophrenia on patients, caregiv-
ers and society as a whole. The high costs of inpatient hospital care demonstrate 
the benefits of an effective prevention of relapse associated with hospitalization. 
Programs for the reintegration of schizophrenic patients into the labor market have 
a high potential to reduce the costs of schizophrenia considering the high burden 
of lost production and the early onset of the disease.
PMH21
a Model To esTiMaTe THe HealTH sysTeM Burden of PresCriPTion 
oPioid aBuse in euroPe
Shei A.1, Hirst M.2, Kirson N.Y.1, Enloe C.J.1, Birnbaum H.G.1, Dunlop W.2
1Analysis Group, Inc., Boston, MA, USA, 2Mundipharma International Limited, Cambridge, UK
Objectives: Prescription opioid (“RxO”) abuse has not been regarded as a major 
problem in Europe so far, but a lack of reliable data hinders the assessment of this 
problem. This study aimed to derive estimates of the prevalence and excess costs 
of RxO abuse in the five largest European countries (France, Germany, Italy, Spain, 
and UK; “EU5”). MethOds: Data from the European Monitoring Centre for Drugs 
and Drug Addiction and the UN Office on Drugs and Crime, on the prevalence of 
problem opioid abuse and the share of opioid abuse patients who report using 
non-heroin opioids, were used to estimate the prevalence of RxO abuse in the EU5. 
The costs of RxO abuse were calculated by applying published estimates of the 
excess health care costs of RxO abuse to country-specific estimates on the costs 
of chronic pain. Sensitivity analyses varied assumptions surrounding the preva-
lence of opioid abuse patients in the general population and the estimates of the 
excess costs of RxO abuse in the EU5. Results: The prevalence of RxO abuse, in 
the general population, varied between the EU5 countries, ranging from 0.7 per 
10,000 to 13.7 per 10,000. In the base case scenario, the total annual health system 
costs of RxO abuse across all EU5 countries were estimated to be € 323 million; results 
of sensitivity analyses ranged from € 98 million to € 730 million. These cost estimates 
included health system costs only; indirect costs were not included. cOnclusiOns: 
RxO abuse imposes a burden on EU5 health systems. Future research should exam-
ine trends in the prevalence and total economic burden of RxO abuse in Europe 
over time and assess the potential benefits of abuse-deterrent formulations, which 
published research suggests have been associated with a significant relative reduc-
tion in rates of diagnosed opioid abuse.
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Objectives: This study aimed to understand the impact of providing care for 
adults with schizophrenia on productivity, daily activities and resource utilization 
in the 5EU. MethOds: Data from the 2010-2011 and 2013 5EU (France, Germany 
Italy, Spain, UK) National Health and Wellness Survey, an online questionnaire 
of a nationwide sample of adults (18+ years) was analyzed. Schizophrenia 
caregivers (n= 398) were matched to non-caregivers (n= 158,989) and other car-
egivers (n= 14,341) on baseline characteristics (sociodemographics, BMI, comor-
bid status) via propensity scores (1: 2). Outcome measures included health care 
utilization (type/number of resources used within the past 6 months) and Work 
Productivity and Activity Impairment questionnaire-based scores. Chi-square 
tests and ANOVAs were used to determine significant differences between 
schizophrenia caregivers vs. non-caregivers and other caregivers (e. g., cancer, 
Alzheimer’s). Results: The average age of schizophrenia caregivers was 45.3 
(SD= 15.8 years), 59.6% were female, and 52.5% were currently employed. After 
matching, schizophrenia caregivers reported greater activity impairment (38.4% 
vs. 26.1%), more health care provider visits (8.0 vs. 5.7), emergency room visits 
(0.9 vs. 0.2) and hospitalizations (0.8 vs. 0.1) than non-caregivers, all p< 0.001. 
Amongst employed respondents, schizophrenia caregivers reported greater 
absenteeism (12.4% vs. 5.6%), presenteeism (29.9% vs. 17.5%), and overall work 
impairment (35.0% vs. 20.7%) than non-caregivers, all p< 0.001. Comparing schizo-
phrenia caregivers and other caregivers, schizophrenia caregivers reported more 
activity impairment (38.4% vs. 32.3%) and health care provider visits (8.0 vs. 
